Rayno Life Science Portfolio 2011 H1 Update-Biopharm Big Winners:BIIB, CBST, REGN, SGEN
2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most ETF's and Life Science mutual funds. Our two recommended biotech ETF's for balancing and overweighting were FBT up 13.3% and IBB up 15.3%. Returns could...
Trends From BIO International Conference: Biotech Sector Performance YTD,MTD
The 2011 Bio Meeting was well attended surpassing last year's number around 15,000. International participation continues to grow with 37% of attendees outside of the U.S. Virtually every country that has industry and universities is looking at biotech development (BIO will release official...
BIO International Convention This Week June 27-30; News on AMGN,GILD
We will be attending the BIO Meeting in Washington DC and will not be posting as usual. Note that there were two news items over the weekend on our portfolio stocks: A positive article on Gilead (GILD) in Barron's. Gilead Sciences Shares Could Rally - Barrons.com Another article in Barron's...
Wild Day on Wall Street: Did the RoboTraders Take Over?
Techs and Biotechs Turn Around Its up- its down- its way down -its coming back.At the end of the day NASDAQ recovered up 0.66% after being down more than 1.4%, the Dow was down 0.49% and the S&P down o.28%. Crosscurrents were too numerous to cover: plunge in oil from emergency release from...
MicroCaps Revisited: CONX, ICCC, IVD
Last December we reviewed three low market cap diagnostic stocks that had product revenue, deal or news potential and value. All are up from our last review and Immucell(ICCC $6.97) has appreciated 100% and still has a market cap of only $20M.Immucell is focused in the beef and dairy industries...